Cambria Investment Management L.P. Invests $700,000 in Abbott Laboratories $ABT

Cambria Investment Management L.P. acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,226 shares of the healthcare product maker’s stock, valued at approximately $700,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cloud Capital Management LLC purchased a new stake in shares of Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories during the third quarter worth about $31,000. Delos Wealth Advisors LLC purchased a new position in Abbott Laboratories during the second quarter worth about $32,000. Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories in the 3rd quarter worth about $33,000. Finally, Copia Wealth Management purchased a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $38,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $105.58 on Friday. The firm has a market capitalization of $183.88 billion, a PE ratio of 28.38, a price-to-earnings-growth ratio of 1.71 and a beta of 0.74. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $139.06. The firm has a 50-day moving average price of $112.75 and a 200-day moving average price of $123.09. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period in the prior year, the company posted $1.34 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s payout ratio is presently 67.74%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were bought at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 3,055 shares of company stock worth $353,097 over the last quarter. 0.46% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of research analyst reports. Sanford C. Bernstein dropped their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Barclays dropped their target price on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Raymond James Financial decreased their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Royal Bank Of Canada lowered their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $136.16.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.